CEDOC, Chronic Diseases Research Centre, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisbon, Portugal.
Adv Exp Med Biol. 2020;1219:311-333. doi: 10.1007/978-3-030-34025-4_16.
Lung cancer is the leading cause of cancer-related deaths worldwide in both men and women. Conventional chemotherapy has failed to provide long-term benefits for many patients and in the past decade, important advances were made to understand the underlying molecular/genetic mechanisms of lung cancer, allowing the unfolding of several other pathological entities. Considering these molecular subtypes, and the appearance of promising targeted therapies, an effective personalized control of the disease has emerged, nonetheless benefiting a small proportion of patients. Although immunotherapy has also appeared as a new hope, it is still not accessible to the majority of patients with lung cancer.The metabolism of energy and biomass is the basis of cellular survival. This is true for normal cells under physiological conditions and it is also true for pathophysiologically altered cells, such as cancer cells. Thus, knowledge of the metabolic remodelling that occurs in cancer cells in the sense of, on one hand, surviving in the microenvironment of the organ in which the tumour develops and, on the other hand, escaping from drugs conditioned microenvironment, is essential to understand the disease and to develop new therapeutic approaches.
肺癌是全世界男性和女性癌症相关死亡的主要原因。传统化疗未能为许多患者提供长期益处，在过去十年中，人们在理解肺癌的潜在分子/遗传机制方面取得了重要进展，从而揭示了其他几种病理实体。考虑到这些分子亚型以及有前途的靶向治疗方法的出现，疾病的有效个体化控制已经出现，但仅使一小部分患者受益。尽管免疫疗法也作为新的希望出现，但大多数肺癌患者仍无法获得该疗法。能量和生物量的代谢是细胞存活的基础。在生理条件下，正常细胞如此，病理生理改变的细胞（如癌细胞）也是如此。因此，了解癌细胞发生的代谢重编程对于理解疾病和开发新的治疗方法至关重要，这种代谢重编程一方面是为了在肿瘤发生的器官的微环境中存活，另一方面是为了逃避药物调节的微环境。
